Our CEO Immanuel Lerner will be attending & presenting at the NextGen Biomed 2025 in London, March 12-13
Join our CEO, Immanuel Lerner for insights on AI-driven peptide drug discovery:📅 March 12:🗝 Keynote – Orally Available Peptides | 9:55 AM💡 Panel – Novel Peptide Therapeutics | 12:30 PM 📅 March 13:🎙 Moderator – Optimizing Drug Candidates | 2:15 PM
Our CEO and co-founder, Dr. Immanuel Lerner and our Advisory Board Member, Dr. Sarah Benson-Konforty will attend the J.P. Morgan Global Healthcare Conference
Join them at the J.P. Morgan 43rd Annual Healthcare Conference 2025, which will take place 13-16 January 2025 in San Francisco, CA, USA.Mr. Lerner will also participate in the Executive Roundtable Wuxi Global Forum, and host a table on Jan 14th from 5-6pm PST. You can reserve a spot here >> https://lnkd.in/d6qhfYWi
Our CEO Immanuel Lerner will be presenting at the DDIF 15th Annual Drug Discovery Innovation Forum in Berlin on September 5th
Our CEO Immanuel Lerner has been selected to speak at the #DDIF 15th Annual Drug Discovery Innovation Forum in Berlin, on September 4-5, 2024!
Our COO Maayan Elias Robicsek will attend Biomed Israel 2025, May 21-23/2024
Our COO Maayan Elias Robicsek is attending Biomed Israel 2025! Come and say hello to learn about our AI drug discovery platform
Dr. Sarah Benson-Konforty joining the Board of Directors and Executive Committee of the AAIH
Pepticom is excited to be taking an active role in shaping the future of AI in healthcare — Congratulations to Dr. Sarah Benson-Konforty, MD for joining the Board of Directors and Executive Committee of the The Alliance for Artificial Intelligence in Healthcare (AAIH)Â
Visit us at BIOMED Israel May 16-18
Join us at booth #3 in the Start-Up Pavilion on May 16th, at BIOMED 2023, Israel’s largest life sciences conference.
“Exploration Science” episode hosting our CEO Immanuel Lerner, and Head of Research, Amit Michaeli
Dr. Wendy Hartsock hosted our CEO, Immanuel Lerner, and Head of Research, Amit Michaeli on an episode of CEM Corporation‘s “Exploration Science”. They discussed the advantages of employing biocomputational AI to accelerate peptide discovery.You can tune in to the whole interview here:Youtube: http://ow.ly/SkgW50NPnmvSpotify: http://ow.ly/YTON50NPo0S
Pepticom joined The Alliance for Artificial Intelligence in Healthcare (AAIH)
The AAIH is a coalition of technology developers, pharmaceutical companies, and research organizations who share our goal of leveraging #AI to advance the quality of healthcare, with a special focus on AI-guided pharmaceutical development.Our advisor, Sarah Benson-Konforty, will attend our first AAIH Annual Members Meeting this May 17-18th in San Francisco.
Our CEO and co-founder, Dr. Immanuel Lerner will be speaking at TIDES Asia 2023
Dr. Immanuel Lerner, CEO and co-founder of Pepticom, will speak at the TIDES Asia conference between March 7-9. His lecture will be about The Potential and Current Application of Artificial Intelligence in Peptide Drug Discovery. The conference will take place in Kyoto, from March 7-9, and he will be available for meetings there as well […]
JP Morgan Healthcare Conference, San Francisco, January 9-10, 2023
The Pepticom Ltd. team, Our CEO Immanuel Lerner and Sarah Benson-Konforty, MD are attending the conference. You can meet them at our booth at the Health Innovation Lounge, the on-site hub of the Israeli health, tech & innovation community, and is located at 447 Sutter Street – a 2 min walk from the Westin St. Francis Hotel.